Selection of oral agents in the management of type 2 diabetes by Pirie, F
PATHOGENESIS OF TYPE 2 
DIABETES
The hyperglycaemia of type 2 diabetes
develops when pancreatic β-cell insulin
secretion is insufficient to compensate for
the prevailing degree of insulin resistance.
In the initial stages, postprandial hyper-
glycaemia occurs, but with progression,
fasting hyperglycaemia also develops. In
most people with type 2 diabetes, the dis-
order is a condition of both insulin resis-
tance and β-cell dysfunction in different
proportions. It appears that both compo-
nents are required for the clinical expres-
sion of the disease.1
Rare conditions exist in which overt dia-
betes develops with either extreme insulin
resistance alone or severe defects in
insulin secretion alone, without the corre-
sponding metabolic defect. Insulin resis-
tance appears to be the initial metabolic
defect in most subjects destined to devel-
op the disease and is often demonstrable
many years before the onset of any abnor-
mality in glucose tolerance.2,3 Evidence in
favour of the presence of β-cell dysfunc-
tion was provided by the United Kingdom
Prospective Diabetes Study (UKPDS), in
which it was estimated that approximately
50% of β-cell function is lost by the time
type 2 diabetes is diagnosed.4 In addition,
the UKPDS showed that β-cell function
continued to decline over time, indicating
that type 2 diabetes is a progressive dis-
ease.
Insulin resistance commonly occurs in
association with obesity and the relation-
ship between insulin sensitivity and body
mass index (BMI) has been shown in
numerous studies.5 Not all obese subjects
with insulin resistance develop diabetes,
however, thus substantiating the fact that
an additional factor (β-cell dysfunction) is
required for the disease to develop.
Furthermore, at least some of the β-cell
dysfunction appears to be reversible by
optimal glycaemic control.6 In the early
stages of the disease, improvement in
insulin secretion through optimal gly-
caemic control may be sufficient to
induce clinical remission for a variable
length of time.
The predominant metabolic disturbances
which result from combined insulin resis-
tance and inadequate insulin secretion
include decreased glucose uptake by
skeletal muscle and liver, decreased 
hepatic glycogen synthesis and increased
hepatic glucose production. Insulin resis-
tance at the level of the adipocyte causes
increased lipolysis, resulting in an increase
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in circulating free fatty acids with
deleterious effects on both insulin
sensitivity and insulin secretion
(lipotoxicity).
Type 2 diabetes is classified as a
single entity by the World Health
Organisation, but is qualified as
being due to either predominant
insulin resistance or predominant
insulin secretory dysfunction,7
which means that the disorder is
heterogeneous. Population-based
prevalence studies have also shown
ethnic heterogeneity.8 Application
of a common therapy to a condi-
tion with a uniform clinical expres-
sion (hyperglycaemia) but variabili-
ty in the pathogenetic factors, is
not logical. Clinical judgement is
needed to select the most suitable
therapies to treat hyperglycaemia
in individual cases. Recognising
that the disease is, in all probabili-
ty, inexorably progressive despite
optimal glycaemic control, is criti-
cal to the long-term follow-up of
patients with type 2 diabetes. This
requires continued surveillance of
metabolic control and correspond-
ing adjustment of therapy in all
cases.
The UKPDS demonstrated that
good glycaemic control can result
in reduction of microvascular com-
plications of diabetes.4 This means
that any clinician managing
patients with type 2 diabetes must
ensure that glycaemic targets are
achieved and maintained as strictly
as possible in each individual case.
The Society for Endocrinology,
Metabolism and Diabetes of South
Africa (SEMDSA) has published
guidelines for metabolic control
and these include a fasting glucose
concentration of 4 - 6 mmol/l,
postprandial glucose concentration
of 4 - 8 mmol/l and glycated
haemoglobin level < 7.0%.9
Both non-pharmacological and
pharmacological interventions can
help attain these goals. Non-phar-
macological interventions include
weight loss through calorie-restrict-
ed diets and regular physical exer-
cise. Both are effective in reducing
hyperglycaemia and should be the
initial management in most sub-
jects with newly diagnosed type 2
diabetes.10,11 Although diet and
exercise will be insufficient as sole
therapies for long-term manage-
ment in most cases, they should
remain part of the management,
since drug therapy is more effective
in subjects on continued diet and
exercise programmes.10,11
Pharmacological therapy includes
the oral agents and insulin. Insulin
therapy is not discussed further,
other than saying that it is proba-
bly a reality for most subjects with
long-term type 2 diabetes, if gly-




A number of classes of agents have
been approved for the management
of type 2 diabetes mellitus and it is
likely that the list will continue to
expand as novel therapies are
introduced. Each group of agents
differ in terms of mechanism of
action and advantages and disad-
vantages. Broad understanding of
pathogenetic mechanisms of type 2
diabetes and the mechanism of
action of individual drugs, allows
tailoring of therapy in individual
cases. The classes of agents in gen-
eral clinical use are:
• sulphonylureas









Sulphonylureas bind to the SUR 1
subunit of the KATP channel, locat-
ed on the β-cell surface membrane,
resulting in the closure of ATP-
sensitive potassium (K+) channels.
This inhibits K+ efflux from the
cell, resulting in depolarisation of
the cell with subsequent opening of
adjacent voltage-dependent L-type
calcium (Ca2+) channels. Intra-cel-
lular Ca2+ levels increase, acting as
the second messenger for insulin
secretion and insulin is released in
a biphasic manner, proportional to
the intracellular Ca2+ concentra-
tion. Sulphonylureas augment
endogenous insulin secretion and
partially overcome the β-cell
defect, but generally have a slow
onset of action and relatively pro-
longed effect, resulting in both
postprandial and fasting increase in
insulin secretion. As a group, the
sulphonylureas have a relatively
weak effect on postprandial hyper-
glycaemia and a greater effect on
fasting hyperglycaemia.12
There are a number of different
sulphonylureas, broadly distin-
guished into first- and second-gen-
eration agents according to the
date of release for clinical use
(Table I).
Most of the sulphonylureas have
inactive metabolites, the major
exception being acetohexamide —
the metabolites of this compound
have 2.5 × the activity of the origi-
nal molecule. Of the newer agents,
Recognising that the
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glibenclamide has a more sustained
effect on the β-cell than the other
agents and this translates into clini-
cal experience of more frequent
and severe hypoglycaemic reactions
as compared with gliclazide, glip-
izide and glimepiride.
All sulphonylureas have a common
sulphonylurea moiety, which con-
fers the class effect, but each dif-
fers chemically in the side chains
of the molecule. It is these chemi-
cal differences that confer different
properties on each agent. For
example, gliclazide has been
reported to inhibit platelet adhe-
sion and increase tissue plasmino-
gen activator levels13 and glimepiri-
de has been reported to bind less
avidly to the myocardial KATP chan-
nel than glibenclamide and thus
reduce ischaemic pre-conditioning
less than glibenclamide.14 Whether
these added effects have clinical




There are two agents in this group
— repaglinide and nateglinide.
Repaglinide
Repaglinide has a mechanism of
action similar to the sulphony-
lureas except that it binds to the 
β-cell SUR 1 KATP subunit at a site
distinct from that of the sulphony-






in the timing of
both onset and
offset of action.
The Tmax is in
the region of
30 - 60 minutes
and the T1/2
(elimination
half-life) is in a
similar range.
This results in a rapid burst of
insulin secretion with a rapid offset
of action. Clinically this results in
better post-prandial glycaemic con-
trol than sulphonylureas and less
between-meal hypoglycaemia.
Repaglinide is metabolised in the
liver and there are no active
metabolites.
Nateglinide
Nateglinide is a phenylalanine
derivative that binds to the same
site on the β-cell SUR 1 subunit as
glibenclamide,15 but differs sub-
stantially from glibenclamide in its
rapid association and dissociation
from the receptor (in a manner
analogous to that of repaglinide).
Nateglinide has a more rapid onset
of effect than repaglinide, but also
a shorter duration of action.12
Furthermore, nateglinide has no
effect in the fasting state and
appears to have a glucose concen-
tration-dependent effect on the
degree of insulin secretion.
Biguanides
Metformin is the only biguanide in
clinical use worldwide. Despite
many years of study, the primary
mechanism of action of metformin
is incompletely understood.
Metformin decreases both gluco-
neogenesis and glycogenolysis and
has a relatively small influence on
enhancing peripheral insulin sensi-
tivity.12 Since there is no stimula-
tion of insulin secretion, there is a
negligible risk of hypoglycaemia
with metformin monotherapy.
Metformin is incompletely
absorbed from the gastrointestinal
tract, has a half-life of 1.5 - 3.0
hours and is excreted entirely by
the kidney. During the absorptive
process, endogenous lactate is pro-
duced and it is this property of the
drug that is responsible for the
major adverse effect, namely lactic
acidosis.
Alpha-glucosidase inhibitors
These agents effectively induce a
state of carbohydrate malabsorp-
tion. Complex carbohydrates,
ingested with a meal, are degraded
to oligosaccharides by amylase.
Oligosaccharides are then degrad-
ed to monosaccharides by small-
intestinal α-glucosidase enzymes.
The binding of oligosaccharides to
the α-glucosidase enzymes is com-
petitively inhibited by the α-glu-
cosidase inhibitors and the undi-
gested carbohydrates pass into the
lower small intestine and large
intestine where digestion by bacte-
rial fermentation occurs. These
agents differ from other oral anti-
hyperglycaemic agents in that they
do not act systemically, they
decrease both post-prandial gly-
caemia and post-prandial insulin
secretion and they are not targeted
at a specific pathophysiologic com-
ponent of type 2 diabetes. The only
member of this group available in
South Africa is acarbose.
Thiazolidinediones
The most recent additions to the
available oral antihyperglycaemic
agents are the two currently
approved thiazolidinediones, piogli-
tazone and rosiglitazone. The thia-
zolidinediones, as a group, are
insulin sensitisers and act by bind-
ing to the peroxisome-proliferator-
activated receptor gamma (PPARγ)
family of nuclear receptors. The
activated receptors bind to specific
response elements on nuclear




Tolbutamide 6 - 10
Chlorpropamide 60
Acetohexamide 12 - 18
Second generation
Glibenclamide 24
Gliclazide Up to 24
Glipizide Up to 24
Glimepiride Up to 24
Table I. Sulphonylureas
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transcription of genes involved in
carbohydrate and lipid metabolism.12
The precise mechanism whereby
the modulation of gene transcrip-
tion translates into increasing
insulin sensitivity is unknown. It
has also been demonstrated that
these agents increase the formation
of adipocytes from pre-adipocyte
stem cells, particularly in subcuta-
neous adipose tissue, and subcuta-
neous fat mass may increase by up
to 8%. Thiazolidinediones are
metabolised extensively in the liver
and pharmacokinetics are not sig-
nificantly affected by mild to mod-
erate renal impairment.
Additional effects of thiazolidine-
diones include increase in high-
density lipoprotein levels, reduc-
tion in triglyceride concentrations
and a variable effect on low-density
lipoprotein levels.16 In addition,
there is evidence of improved
endothelial function and possibly
an anti-atherosclerosis effect.




Most studies report a 1 - 2% mean
reduction in HbA1c, compared with
placebo. In the UKPDS, treatment
of 3 867 persons with sulphonyl-
urea compared with diet over 10
years, resulted in 0.9% reduction
of HbA1c, whereas a study of 416
persons with glimepiride versus
placebo over 14 weeks, resulted in
2.5% reduction in HbA1c.16
There is progressive loss of β-cell
function over time and it would be
reasonable to assume that the
capacity of the β-cell to respond to
sulphonylureas would correspond-
ingly diminish and possibly
account for progressive loss of clin-
ical efficacy — so-called ‘secondary
failure’. This phenomenon has
implications for treatment of indi-
vidual cases. There appears to be
comparable efficacy of most cur-
rently used members of the
sulphonylurea group. Studies that
have compared glipizide versus
glibenclamide and glimepiride ver-
sus glibenclamide have shown
equivalent efficacy in terms of
reduction of HbA1c.16 
Non-sulphonylurea insulin 
secretagogues
Repaglinide compared with place-
bo has shown reduction in HbA1c
of 1.7 - 1.9% and nateglinide com-
pared with placebo has shown
reduction in HbA1c of 0.6 - 1.0%.16
Repaglinide was more effective
than troglitazone in a 22-week
study of 256 subjects, but demon-
strated equivalent efficacy with
glibenclamide and metformin in
separate studies.16 By contrast,
nateglinide was less effective than
metformin in a study of 701 sub-
jects over 24 weeks.16 Thus, it
appears that repaglinide is similar
to sulphonylurea agents in terms of
efficacy, but nateglinide is slightly
less potent.
Biguanides 
Metformin has been the subject of
many studies, including recent tri-
als, since it was re-introduced in
the USA in 1995. Mean reduction
in HbA1c ranges from 0.8% to
3.0% (compared with diet or
placebo).16 In the UKPDS, there
appeared to be specific advantages
to therapy with metformin in that
metformin showed a greater effect
than chlorpropamide, gliben-
clamide or insulin for any diabetes-
related endpoint all-cause mortality
and stroke.17 Metformin compared
with gliclazide, glipizide, gliben-
clamide and chlorpropamide, has
shown equivalent efficacy in terms
of reduction in HbA1c.16
Alpha-glucosidase inhibitors
Comparison of acarbose with
placebo has shown reduction of
HbA1c ranging from 0.4% to 1.3%
— somewhat smaller changes in
glycaemia than have been observed
with most of the other oral agents.
Acarbose compared with met-
formin 850 mg bd and gliben-
clamide mean dose 4.3 mg daily
showed equal efficacy, but the
comparison with suboptimal doses
(of metformin and glibenclamide
respectively) is perhaps not valid.
Thiazolidinediones
Both pioglitazone and rosiglitazone
are superior to placebo, with
reductions in HbA1c ranging from
1.1% to 1.5%.16 A comparison of
pioglitazone 45 mg daily, rosiglita-
zone 8 mg daily and troglitazone
600 mg daily in 3 consecutive
series of patients showed similar
reduction of HbA1c after 2 - 4
months of therapy.18 Comparison
of troglitazone with metformin and
glibenclamide has shown equiva-
lent efficacy.16
Clinical efficacy of combination
therapy with oral antihypergly-
caemic agents
Given the presence of a number of
different pathophysiological defects
in subjects with type 2 diabetes
and the ongoing reduction in β-cell
secretory capacity, using different
oral agents with different mecha-
nisms of action is a rational
approach to management. Studies
that have compared adding a sec-
ond agent with the addition of
placebo, have shown that the
reduction in HbA1c by the addition
of the second agent is approxi-
mately equal to that which would
have been observed with mono-
therapy with that agent. The reduc-
tion is additive rather than syner-
gistic.16 For example, in the
UKPDS, addition of metformin to
sulphonylurea resulted in an addi-
tional reduction in HbA1c of 0.6%
compared with the sulphonylurea
alone.
An unexpected and as yet unex-
plained finding in the UKPDS was
the observation that addition of
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metformin to sulphonylurea-treat-
ed patients was associated with a
96% increased risk of death com-
pared with therapy with sulphony-
lurea alone.17 This is thought to be
a consequence of the small sample
size of this particular analysis and
has not been repeated in other
studies. Other examples of mono-
therapy compared with combina-
tion therapy include:
• the addition of acarbose to met-
formin versus placebo, which
resulted in 0.7% additional
reduction in HbA1c
• the addition of rosiglitazone to
metformin, which resulted in an
additional 1.2% reduction in
HbA1c, compared with the addi-
tion of placebo
• the addition of pioglitazone to
metformin versus placebo,
which resulted in 0.8% addi-
tional reduction in HbA1c.16
Adverse effects of oral 
antihyperglycaemic agents
All oral agents used in the manage-
ment of type 2 diabetes are contra-
indicated in pregnancy, in type 1
diabetes and in children.
Sulphonylureas
The major potential adverse effect
of therapy with sulphonylurea
agents is hypoglycaemia.
Glibenclamide and chlor-
propamide were both used in the
UKPDS and both were associated
with major hypoglycaemic events
(0.4% for chlorpropamide and
0.6% for glibenclamide over 10
years), but these were less frequent
than those recorded with insulin
therapy (2.3% over 10 years).4 As
would be expected, the subjects
treated intensively experienced
more major hypoglycaemic events
than those treated conventionally
and there were more major hypo-
glycaemic episodes in the first
years of the study than in the latter
years of the study. This probably
relates to the presence of a greater
number of responsive β-cells earlier
in the condition. The progressive
loss of β-cell mass translates into
less hypoglycaemia, but also less
efficacy. There is also an associa-
tion with weight gain and 2 - 5 kg
increase in body mass is usual.16
Non-sulphonylurea insulin 
secretagogues
Both the agents in this group have
the potential to induce hypogly-
caemia, although less than that
which occurs with sulphonylureas
because of the rapid dissociation of
the compounds from the β-cell and
the resultant rapid ‘on-off ’ effect
on insulin secretion. Thus, particu-
larly in the preprandial period,
there is less glycaemic-insulinaemic
mismatching as compared with
sulphonylureas. Similarly, weight
gain is less problematic. A disad-
vantage, rather than an adverse
effect, is the need for three times
daily (meal-related) dosing.
Biguanides
The two major adverse effects of
metformin are gastrointestinal
intolerance and lactic acidosis.
Gastrointestinal intolerance may be
reduced by dosing with meals and
increasing doses slowly, but there
remains a proportion of subjects
who still cannot tolerate the
abdominal cramps, bloating and
diarrhoea that may accompany
metformin therapy. Lactic acidosis
can be avoided if the drug is not
used in conditions where endoge-
nous lactate production is inher-
ently increased or where renal




• serum creatinine > 132 µmo/l in
men and > 123 µmol/l in
women 
• congestive cardiac failure requir-
ing medical therapy 
• abnormal liver function 
• severe obstructive lung disease
with hypoxaemia 
• age > 80 years 
• in the perioperative period (tem-
porary discontinuation) 
• radiological procedures using
intravenous contrast material
(temporary discontinuation)




An infrequent adverse effect of
metformin is the development of
vitamin B12 deficiency and haemo-
globin and vitamin B12 levels
should be checked periodically
(annually) in subjects on long-term
metformin therapy.
Alpha-glucosidase inhibitors
The inhibition of carbohydrate
absorption, induced by therapy
with these agents, leads to the fre-
quent gastrointestinal adverse
effects of α-glucosidase inhibitors
— bloating, flatulence and diar-
rhoea. These effects are minimised
by starting with smaller doses and
increasing slowly, and they do
improve with continued use. Apart
from this, the agents are safe and
free from systemic toxicity.
Thiazolidinediones
Troglitazone, the prototype thiazo-
lidinedione, was introduced into
clinical use in the USA in 1997
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and withdrawn in March 2000 fol-
lowing several episodes of severe
liver toxicity. Since the introduc-
tion of the two newer thiazolidine-
diones, pioglitazone and rosiglita-
zone, no reports of comparable
hepatic toxicity have appeared.
Despite this, there is still a recom-
mendation to monitor liver func-
tion after initiating therapy with
these agents.
Apart from concern over liver toxi-
city, the only clinically significant
adverse effect noted has been fluid
accumulation and a corresponding
exacerbation of congestive heart
failure. The reason for fluid reten-
tion is unknown, but appears to be
worse in subjects on insulin thera-
py, in whom reduction in haemat-
ocrit by up to 15% may occur.12
Weight gain is seen with thiazo-
lidinedione therapy, partly due to
fluid accumulation and partly due
to the development of increased
adipose tissue in subcutaneous (as
opposed to visceral) sites.
Hypoglycaemia does not occur
with thiazolidinedione monotherapy.
Oral antihyperglycaemic agents
available in South Africa
Table II shows the preparations
licensed for use in subjects with
type 2 diabetes (as monotherapy
and in combination) that are avail-




The newly diagnosed type 2 dia-
betic requires initiation of therapy
with diet, exercise and lifestyle
modification. Exercise programmes
must take account of co-morbidi-
ties, especially ischaemic heart dis-
ease. Subjects who have marked
hyperglycaemia at presentation
(plasma glucose > 15 mmol/l) or
who are severely symptomatic will
require drug therapy from diagno-
sis, in addition to lifestyle and
dietary measures.
Choice of initial therapy is based
on the assumption that the more
overweight the person is, as mea-
sured by BMI, the greater the
degree of insulin resistance (Table
III). Conversely, the assumption is
that the leaner the subject, the
greater the insulin sensitivity and
the greater the β-cell dysfunction.
This latter group of subjects, how-
ever, may harbour late-onset type 1
diabetes and must be closely
observed as decompensation to
overt type 1 diabetes may occur.
References available on request.
Generic name Trade name Dose range Manufacturer
Sulphonylureas
Acetohexamide Dimelor 250 mg daily - 1 500 mg daily Quatromed
Hypomide Aspen
Chlorpropamide Diabinese 250 mg daily - 500 mg daily Pfizer
Diabitex Salters





Glipizide Minidiab 2.5 mg daily - 30 mg daily Pharmacia & Upjohn





Glimepiride Amaryl 1 mg daily - 8 mg daily Aventis
Non-sulphonylurea secretagogues
Repaglinide Novonorm 0.5 mg tds - 4 mg tds Novo Nordisk
Nateglinide Starlix 120 mg tds - 180 mg tds Novartis
Biguanides
Metformin Glucophage 500 mg daily - 1 g bd Merck
Rolab-Metformin Rolab
Alpha-glucosidase inhibitors
Acarbose Glucobay 50 mg tds - 200 mg tds Bayer
Thiazolidinediones
Pioglitazone Actos 15 mg daily - 45 mg daily Eli-Lilly
Rosiglitazone Avandia 2 mg daily - 8 mg daily Smith-Kline-Beecham
Table II. Oral antihyperglycaemic agents available in South Africa
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IN A NUTSHELL 
Type 2 diabetes is a heterogeneous condition characterised by varying degrees of both insulin resistance and insulin defi-
ciency (due to pancreatic β-cell dysfunction).
Type 2 diabetes is a progressive disease, with continued deterioration in β-cell function occurring in the majority of affected
persons.
Oral antihyperglycaemic therapy is adjunctive to diet, exercise and lifestyle management.
Five classes of oral antihyperglycaemic agents are available for clinical use in South Africa, each with specific advantages
and disadvantages and broadly designated as ‘secretagogues’ and ‘sensitisers’.
Attempting to match therapy (based on mechanism of action of the pharmacological agent) with perceived pathophysiology
is a logical approach to a complex metabolic disorder, but continued surveillance of metabolic control and adjustment in
doses are usual.
Combination therapy is needed in the majority of persons with type 2 diabetes.
Insulin therapy is a reality for most persons with type 2 diabetes, if metabolic targets are to be attained and maintained.
* If there is severe renal dysfunction (serum creatinine > 400 µmol/l), insulin therapy is indicated.
† Thiazolidinediones are contraindicated in class III or IV heart failure. 
‡ In principle, the sequence of choice should be: sulphonylurea/metformin, followed by non-sulphonylurea secretagogues (if hypoglycaemia occurs with sulphonylurea), 
followed by thiazolidinedione (unless there is clinical suspicion of severe insulin resistance). This is in view of the cost of the thiazolidinediones.
Table III. Recommended oral antihyperglycaemic therapy
Initial therapy
BMI > 25 kg/m2
• Normal renal and cardiac
function: metformin





BMI ≤ 25 kg/m2
• Sulphonylurea
3 - 4-month follow-up
Targets achieved
No change in therapy, continue with
observation and regular review
Failure to achieve targets
• Adverse effects with metformin: 
change to thiazolidinedione 
monotherapy
• Hypoglycaemia with sulphonylurea: 
change to non-sulphonylurea 
secretagogues
• Maximal dose metformin: add
sulphonylurea, non-sulphonylurea  
secretagogues or thiazolidinedione‡
• Maximal dose sulphonylurea: add 
metformin or thiazolidinedione‡
• Maximal dose thiazolidinedione: 
add metformin if overweight and 
sulphonylurea if lean
6 - 12-month follow-up
Targets achieved
No change in therapy, continue
with observation and regular
review
Failure to achieve targets
• If still on monotherapy, add a
second agent as above
• If on 2 agents in maximal dose,  
insulin therapy is indicated
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